Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Assessment of the Rectum and Anus01:25

Assessment of the Rectum and Anus

Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Assessment of the Gastrointestinal System I: Subjective Data01:17

Assessment of the Gastrointestinal System I: Subjective Data

Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems related to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease.

Basic & clinical pharmacology & toxicology·2026
Same author

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

EULAR rheumatology open·2026
Same author

Amylase and lipase in alcohol-induced acute pancreatitis: Time to rethink diagnostic thresholds?

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same author

European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations.

United European gastroenterology journal·2026
Same author

Fulminant Hepatic Failure Following Initiation of Abiraterone in Metastatic Prostate Cancer: A Fatal Adverse Drug Reaction.

Case reports in hepatology·2026
Same author

Digitally supported, patient-initiated care: Maintaining control of inflammatory bowel diseases while achieving high patient satisfaction.

International journal of medical informatics·2026

Related Experiment Videos

Validated tools for evaluating opioid-induced bowel dysfunction.

Anne Estrup Olesen1, Asbjørn Mohr Drewes

  • 1Mech-Sense, Department of Gastroenterology, Aalborg Hospital, Aarhus University Hospital, Denmark. aeo@mech-sense.com

Advances in Therapy
|March 26, 2011
PubMed
Summary
This summary is machine-generated.

Opioid-induced bowel dysfunction (OIBD) affects the entire gut, not just constipation. Current evaluation methods primarily focus on constipation, neglecting other prevalent OIBD symptoms like nausea and bloating.

Related Experiment Videos

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Pain Management

Background:

  • Opioid treatment for pain can cause significant gastrointestinal adverse effects.
  • Opioid-induced bowel dysfunction (OIBD) is a prevalent issue, often misidentified solely as constipation.
  • OIBD encompasses a range of symptoms beyond constipation, including nausea, reflux, bloating, and anorexia.

Purpose of the Study:

  • To provide an overview of evaluation methods for opioid-induced bowel dysfunction (OIBD).
  • To highlight the challenges in assessing OIBD symptoms.
  • To focus on the evaluation of constipation as the most frequently reported OIBD symptom.

Main Methods:

  • Review of existing literature on OIBD evaluation.
  • Discussion of validated methods for assessing gastrointestinal symptoms.
  • Analysis of subjective and objective measures for constipation assessment.

Main Results:

  • Validated methods for evaluating OIBD symptoms are scarce, particularly for non-constipation symptoms.
  • Systematic evaluation has predominantly focused on constipation, the most reported symptom.
  • Subjective constipation assessments show limited correlation with objective measures like transit time.

Conclusions:

  • There is a need for comprehensive evaluation tools for the full spectrum of OIBD symptoms.
  • Current assessment strategies for OIBD are insufficient and often focus narrowly on constipation.
  • Improved evaluation methods are crucial for understanding drug effects on OIBD.